CAPOX新辅助化疗对比放化疗治疗MRF未受侵犯的局部进展期直肠癌(CONVERT):III期试验初步结果
CONVERT试验比较CAPOX新辅助化疗与卡培他滨新辅助放化疗在MRF未受侵犯的局部进展期直肠癌中的疗效。589例患者随机接受治疗,nCT组pCR率11.0%、nCRT组13.8%(P=0.33),降期率分别为40.8%和45.6%(P=0.27)。nCT组围手术期远处转移率(0.7% vs 3.1%,P=0.03)和预防性回肠造口率(52.2% vs 63.6%,P=0.008)更低。
要点
- CAPOX新辅助化疗与放化疗的pCR率和降期率相似
- CAPOX组围手术期远处转移率和预防性回肠造口率更低
- CAPOX可作为MRF未受侵犯局部进展期直肠癌的新辅助治疗选择
核心结论
- CAPOX新辅助化疗达到与放化疗相似的pCR率和降期率,且围手术期远处转移率和预防性回肠造口率更低。
研究设计与样本
- III期随机对照试验,2014年6月至2020年10月入组,663例初筛患者中589例接受分配治疗(nCT组300例,nCRT组289例)。
- 纳入距肛缘12 cm以内、MRF未受侵犯的局部进展期直肠癌患者。
主要发现
- nCT组pCR率11.0%(95%CI 7.8-15.3%),nCRT组13.8%(95%CI 10.1-18.5%),P=0.33。
- nCT组降期(ypStage 0-1)率40.8%(95%CI 35.1-46.7%),nCRT组45.6%(95%CI 39.7-51.7%),P=0.27。
- nCT组围手术期远处转移率0.7%,nCRT组3.1%,P=0.03。
- nCT组预防性回肠造口率52.2%,nCRT组63.6%,P=0.008。
- nCT组4例因局部进展接受挽救性nCRT;nCT组2例和nCRT组5例达临床完全缓解并接受非手术治疗。
关键数值与推荐
- nCT方案:CAPOX 4周期(奥沙利铂130 mg/m2静滴第1天,卡培他滨1000 mg/m2每日两次口服14天,每3周重复)。
- nCRT方案:卡培他滨825 mg/m2每日两次口服同步放疗(50 Gy/25次,每周5天)。
临床怎么用
- 对于MRF未受侵犯的局部进展期直肠癌,CAPOX新辅助化疗可作为放化疗的替代选择。
- 需长期随访确认生存获益。
局限性
- 本文报告的是次要终点结果,主要终点局部区域无复发生存尚未报告。
- 需要长期随访确认结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare neoadjuvant chemotherapy (nCT) with CAPOX alone versus neoadjuvant chemoradiotherapy (nCRT) with capecitabine in locally advanced rectal cancer (LARC) with uninvolved mesorectal fascia (MRF). BACKGROUND DATA: nCRT is associated with higher surgical complications, worse long-term functional outcomes, and questionable survival benefits. Comparatively, nCT alone seems a promising alternative treatment in lower-risk LARC patients with uninvolved MRF. METHODS: Patients between June 2014 and October 2020 with LARC within 12 cm from the anal verge and uninvolved MRF were randomly assigned to nCT group with 4 cycles of CAPOX (Oxaliplatin 130 mg/m2 IV day 1 and Capecitabine 1000 mg/m2 twice daily for 14 d. Repeat every 3 wk) or nCRT group with Capecitabine 825 mg/m² twice daily administered orally and concurrently with radiation therapy (50 Gy/25 fractions) for 5 days per week. The primary end point is local-regional recurrence-free survival. Here we reported the results of secondary end points: histopathologic response, surgical events, and toxicity. RESULTS: Of the 663 initially enrolled patients, 589 received the allocated treatment (nCT, n=300; nCRT, n=289). Pathologic complete response rate was 11.0% (95% CI, 7.8-15.3%) in the nCT arm and 13.8% (95% CI, 10.1-18.5%) in the nCRT arm ( P =0.33). The downstaging (ypStage 0 to 1) rate was 40.8% (95% CI, 35.1-46.7%) in the nCT arm and 45.6% (95% CI, 39.7-51.7%) in the nCRT arm ( P =0.27). nCT was associated with lower perioperative distant metastases rate (0.7% vs. 3.1%, P =0.03) and preventive ileostomy rate (52.2% vs. 63.6%, P =0.008) compared with nCRT. Four patients in the nCT arm received salvage nCRT because of local disease progression after nCT. Two patients in the nCT arm and 5 in the nCRT arm achieved complete clinical response and were treated with a nonsurgical approach. Similar results were observed in subgroup analysis. CONCLUSIONS: nCT achieved similar pCR and downstaging rates with lower incidence of perioperative distant metastasis and preventive ileostomy compared with nCRT. CAPOX could be an effective alternative to neoadjuvant therapy in LARC with uninvolved MRF. Long-term follow-up is needed to confirm these results.
引用
- Mei WJ, Wang XZ, Li YF, et al. Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial. Ann Surg. 2022. PMID: 36538627. doi:10.1097/SLA.0000000000005780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。